Literature DB >> 7996139

Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro.

E D D'Souza1, E O'Sullivan, E M Amphlett, D J Rowlands, D V Sangar, B E Clarke.   

Abstract

The protease activity of the hepatitis C virus (HCV) NS3 protein has been investigated using transient expression methods in mammalian cells, as well as in vitro transcription/translation systems. We confirmed that expression of the NS3-5 polyprotein in rabbit reticulocyte lysates results in efficient cis processing at the NS3/NS4 junction. However, processing at the other predicted sites of NS3-mediated cleavage varied markedly in efficiency, the site most susceptible being that between NS5A and NS5B. Time-course analysis of the proteolytic processing of the HCV non-structural precursor showed that the cis cleavage between NS3 and NS4 occurred extremely rapidly. However, efficient cleavage at this position was dependent on the prior removal of the NS2 protein. Furthermore, the presence of uncleaved NS2 sequences on the enzyme severely impeded NS3-mediated proteolysis at downstream sites in the polyprotein. This suggests therefore that efficient cleavage at the NS2/NS3 junction is a pivotal event in HCV replication. During the course of this study a proteolytically inactive mutant of NS3 was characterized carrying a previously unreported amino acid substitution near the proposed active site of the enzyme. Molecular modelling suggested that the amino acid present at this position may influence the conformation of the active site of the enzyme. Recently a number of reports have described a second protease activity, located in the NS2/NS3 region, which is responsible for cleavage at the NS2/NS3 junction. We have identified an isolate of HCV, obtained from a U.K. patient, which has a virtually inactive NS2/NS3 protease. The possible implications of this observation are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7996139     DOI: 10.1099/0022-1317-75-12-3469

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Host cell factor requirement for hepatitis C virus enzyme maturation.

Authors:  L Waxman; M Whitney; B A Pollok; L C Kuo; P L Darke
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

2.  Characterization of an autonomous subgenomic pestivirus RNA replicon.

Authors:  S E Behrens; C W Grassmann; H J Thiel; G Meyers; N Tautz
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

3.  Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease.

Authors:  S S Taremi; B Beyer; M Maher; N Yao; W Prosise; P C Weber; B A Malcolm
Journal:  Protein Sci       Date:  1998-10       Impact factor: 6.725

4.  SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

Authors:  B A Malcolm; R Liu; F Lahser; S Agrawal; B Belanger; N Butkiewicz; R Chase; F Gheyas; A Hart; D Hesk; P Ingravallo; C Jiang; R Kong; J Lu; J Pichardo; A Prongay; A Skelton; X Tong; S Venkatraman; E Xia; V Girijavallabhan; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

5.  Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.

Authors:  P Gallinari; D Brennan; C Nardi; M Brunetti; L Tomei; C Steinkühler; R De Francesco
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

6.  The NS2 protein of hepatitis C virus is a transmembrane polypeptide.

Authors:  E Santolini; L Pacini; C Fipaldini; G Migliaccio; N Monica
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

7.  Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo.

Authors:  A A Kolykhalov; K Mihalik; S M Feinstone; C M Rice
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.